Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Rhea-AI Summary

Curis (NASDAQ: CRIS) announced the closing of a private placement (PIPE) raising up to $80.8 million in gross proceeds, with initial gross proceeds of approximately $20.2 million to the company, before placement agent fees and offering expenses. The PIPE was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, and The Red Hook Fund, and included participation from other new and existing institutional investors as well as members of Curis' management team and board. Laidlaw & Company (UK) Ltd. acted as sole placement agent.

Positive

• Private placement raises $80.8M in gross proceeds
• Initial proceeds of $20.2M received by the company
• Participation from management and board signals insider support

Negative

• PIPE financing may dilute existing shareholders depending on final terms

Key Figures

Total PIPE size $80.8 million Maximum gross proceeds from private placement before fees and expenses

Initial gross proceeds $20.2 million Initial tranche gross proceeds to Curis before fees and expenses

Market Reality Check

$0.8268 Last Close

Volume Volume 1,398,920 vs 20-day average 949,003 shows elevated trading ahead of the financing close. normal

Technical Shares at $0.85 are well below the $1.67 200-day MA and close to the $0.771 52-week low, far from the $3.73 52-week high.

Peers on Argus

CRIS was up 1.15% while peers were mixed: AKTX +2.69%, QTTB +7.51%, but ELEV -2.28%, FBLG -5.28%, GDTC -7.75%, indicating a stock-specific setup around this private placement.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Jan 07	Private placement pricing	Negative	-16.0%	PIPE terms and potential dilution from preferred stock and warrants.
Dec 09	Clinical data update	Positive	-1.5%	Improved uMRD rates in AML triplet study with stable safety profile.
Nov 14	Conference presentations	Positive	+17.7%	Planned emavusertib data presentations at the SNO neuro-oncology meeting.
Nov 06	Earnings and pipeline	Neutral	+2.8%	Q3 2025 loss, limited cash runway, and ongoing emavusertib trial progress.
Oct 30	Earnings call notice	Neutral	+0.0%	Scheduling of Q3 2025 results release and investor conference call.

Pattern Detected

Recent financings for CRIS have coincided with sharp negative reactions, while clinical and corporate updates have produced mixed but mostly aligned moves.

Recent Company History

Over the last few months, Curis has combined serial financings with ongoing clinical and corporate updates. A prior private placement pricing on Jan 7, 2026 was followed by a -15.97% move. Clinical data in AML (uMRD in 5 of 8 patients) on Dec 9, 2025 and presentations at the 30th SNO Meeting on Nov 19–23, 2025 highlighted emavusertib’s development. The Q3 2025 update on Nov 6, 2025 showed ongoing losses but active trial execution. Today’s closing of the private placement operationalizes the financing announced earlier in January.

Market Pulse Summary

This announcement confirms the closing of a previously priced private placement for up to $80.8 million, including initial gross proceeds of about $20.2 million before fees. It follows a pattern of equity and warrant financings used to fund emavusertib development. Recent filings described operating losses, limited prior cash, and listing compliance challenges, underscoring why additional capital was critical. Investors would likely monitor subsequent cash burn, trial milestones, and any further capital raises tied to this structure.

Key Terms

private placement financial

"today announced the closing of its previously announced private placement (the "PIPE financing")"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

pipe financing financial

"closing of its previously announced private placement (the "PIPE financing") for gross proceeds"

Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.

AI-generated analysis. Not financial advice.

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP

LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

In addition to the healthcare-focused institutional investors listed above, the private placement included participation from other new and existing institutional investors, as well as members of the Company's management team and board of directors.

Laidlaw & Company (UK) Ltd. acted as sole placement agent for the PIPE financing.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in a Phase 2 study (CA-4948-203) of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in Chronic Lymphocytic Leukemia. The Company has completed its monotherapy and combination studies in acute myeloid leukemia (AML), with additional resources we plan to continue development of emavusertib as a monotherapy and in combination in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948).

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-announces-closing-of-private-placement-totaling-up-to-80-8-million-in-gross-proceeds-302657173.html

SOURCE Curis, Inc.

FAQ

How much did Curis (CRIS) raise in the January 9, 2026 private placement?

Curis raised up to $80.8 million in gross proceeds from the private placement.

How much initial gross proceeds did Curis (CRIS) receive from the PIPE financing?

The company received approximately $20.2 million in initial gross proceeds, before fees and expenses.

Who led the Curis (CRIS) private placement announced January 9, 2026?

The PIPE was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, and The Red Hook Fund.

Did Curis (CRIS) management participate in the January 2026 PIPE financing?

Yes; the private placement included participation from members of Curis' management team and board of directors.

Who acted as placement agent for Curis (CRIS) private placement?

Laidlaw & Company (UK) Ltd. acted as sole placement agent for the PIPE financing.